Asia Pacific Meningococcal Vaccines Market Size & Outlook
Asia Pacific meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Asia Pacific meningococcal vaccines market highlights
- The Asia Pacific meningococcal vaccines market generated a revenue of USD 373.8 million in 2021.
- The market is expected to grow at a CAGR of 8.4% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2022 to 2030.
Asia Pacific data book summary
| Market revenue in 2021 | USD 373.8 million |
| Market revenue in 2030 | USD 773.1 million |
| Growth rate | 8.4% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Quadrivalent |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.0% of the global meningococcal vaccines market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 141.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 66.32% in 2021. Horizon Databook has segmented the Asia Pacific meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of nonprofit organizations that provide information, train healthcare professionals, support patients affected by meningitis is anticipated to fuel market growth. For instance, Meningitis Centre Australia, Inc. was established by a group of healthcare professionals & parents to raise awareness regarding meningitis by educating community about signs and symptoms of the disease.
Furthermore, Immunization Advisory Centre in New Zealand provides national immunization coordination & policy advice and conducts research on meningitis. Meningococcal vaccines are included in a few national immunization programs in the region.
However, it is highly recommended in many Asian countries for high-risk people. Moreover, increase in government funding in vaccination campaign is increasing market growth. In addition, increasing initiatives such as free vaccination for children are expected to drive immunization rates, thereby boosting market growth.
Reasons to subscribe to Asia Pacific meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific meningococcal vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific meningococcal vaccines market size, by country, 2018-2030 (US$M)
Asia Pacific Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
